Summary of Boundless Bio FY Conference Call Company Overview - **Company**: Boundless Bio (NasdaqGS:BOLD) - **Industry**: Precision Oncology - **Location**: San Diego - **Established**: Approximately six years ago - **Focus**: Addressing unmet needs in oncology, specifically for patients with oncogene amplification-driven tumors, which represent about 25% of all cancer patients [4][10] Core Scientific Insights - **Extrachromosomal DNA (ecDNA)**: A key area of focus for Boundless Bio, identified as a root cause of oncogene amplifications. This DNA is distinct from chromosomal DNA and is not found in healthy tissues [4][8] - **Oncogene Amplifications**: Represent about 25% of cancers, with ecDNA present in approximately 15% of all cancers, particularly in aggressive tumor types like glioblastoma and metastatic ovarian cancer [10][11] - **Current Treatment Landscape**: There is a lack of approved targeted therapies for oncogene amplifications, with the exception of HER2 in breast cancer. Current treatments often default to chemotherapy, which is not specific to the underlying biology [13] Clinical Development and Pipeline - **Current Programs**: - **BBI-355**: In clinical trials, showing activity but facing challenges with toxicity [16][17] - **BBI-825**: Another program in the clinic with ongoing evaluations [16] - **BBI-940**: A new program targeting a novel kinesin, expected to enter first-in-human studies in the first half of 2026 [22][34] Spyglass Platform - **Function**: A proprietary discovery platform used to identify and validate new targets related to ecDNA biology. It utilizes a library of in vitro and in vivo models to differentiate between ecDNA positive and negative tumors [14][15] Key Findings and Learnings - **Clinical Insights**: Early clinical data from BBI-355 has shown responses in specific genetic markers, indicating potential for targeted therapy [17][18] - **Preclinical Data for BBI-940**: Demonstrated good tolerability and anti-tumor activity in various models, with a particular interest in breast cancer as a primary target [25][26] Competitive Landscape - **Current Position**: Boundless Bio does not face immediate competition for the specific kinesin target of BBI-940, as it is believed to be a first-in-class discovery [30] - **Broader Market**: Other companies are working on different kinesins, but Boundless Bio's target is considered non-overlapping, potentially allowing for complementary therapies [31] Industry Trends - **Growing Interest in ecDNA**: The field has seen significant academic interest, with multiple publications and conferences dedicated to ecDNA research. Big Pharma is also showing interest, with companies like Amgen exploring ecDNA biology [35][36] Financial Overview - **Cash Position**: As of the last earnings report, Boundless Bio had approximately $117 million in cash, projected to last into 2028 [38]

Boston Scientific Investor Day Summary Company Overview - **Company**: Boston Scientific - **Industry**: Medical Devices - **Event**: Investor Day Key Points and Arguments Company Vision and Culture - Boston Scientific aims to be a leader in the medical device industry, focusing on "advancing science for life" as a core mission [6][7][21] - The company emphasizes the importance of employee engagement and culture as key differentiators in its success [7][23] Financial Performance and Growth Projections - The company projects **14% to 15% organic growth** for 2025, following a **16% organic growth** in 2024 [8][11] - Anticipated **18% to 19% EPS growth** for the current year [9] - Boston Scientific aims for **10%+ organic growth** over the next three years, outpacing the market CAGR of **9%** [11][12] - The company has a history of meeting or exceeding Investor Day targets, instilling confidence in shareholders [10][11] Business Units and Market Performance - Boston Scientific operates across **eight business units**, with notable growth in **Cardiovascular** and **MedSurg** sectors [9][10] - The company has seen impressive growth in the **Asia Pacific** region, particularly in **China**, which is projected to generate over **$1 billion** in revenue by 2025 [24][28] - The international market, including EMEA and Latin America, represents about **35%** of revenue in 2025, with plans to increase this percentage [25] Innovation and R&D - Boston Scientific is committed to a robust **innovation ecosystem**, integrating R&D, venture capital, and M&A to drive growth [17][18] - The company has made significant investments in **AI and automation** within its manufacturing processes to enhance efficiency [27] - A focus on **category leadership** in specific medical fields, such as neuromodulation and urology, is central to its strategy [12][33] China Market Strategy - Boston Scientific has doubled its revenue and employee base in China over the last five years, significantly outpacing competitors [28][29] - The company has adopted a **localization strategy**, investing in local innovative companies to enhance its portfolio [30][31] - Boston Scientific has successfully navigated the **Volume-Based Purchasing (VBP)** environment, allowing for expanded access to the healthcare system despite price pressures [32] MedSurg and Urology Business Insights - The MedSurg segment, including neuromodulation, urology, and endoscopy, is projected to grow above market rates, driven by a strong pipeline and category leadership [33][48] - The urology market is estimated at **$7 billion**, with expectations for high single-digit growth fueled by extensive product offerings and global expansion [48][49] - Innovations in urology include the **stone-smart ecosystem** aimed at improving surgical outcomes and reducing postoperative infections [52][53] Neuromodulation and Pain Management - The neuromodulation segment focuses on chronic pain and movement disorders, with a goal of high single-digit growth driven by innovative therapies [37][45] - Key growth drivers include the **Intracept therapy** for chronic low back pain and advancements in **Deep Brain Stimulation (DBS)** technologies [40][43] Conclusion - Boston Scientific is positioned for continued growth through a combination of strong financial performance, innovative product development, and strategic market expansion, particularly in underpenetrated international markets [21][24][25][32]